中国北京,2025年12月9日——甘李药业股份有限公司(以下简称“甘李药业”,股票代码:603087.SH)今日宣布与晶泰科技(股票代码:2228.HK)达成代谢疾病领域AI多肽创新药的研发合作及AI技术平台使用授权协议。此次合作将充分发挥甘李药业在代谢疾病领域近30年的深厚积淀与晶泰科技在AI多肽药物研发平台的领先技术优势,在AI赋能多肽药物创新与海外市场拓展中深度协同,围绕新靶点、新机制、...
Source Link中国北京,2025年12月9日——甘李药业股份有限公司(以下简称“甘李药业”,股票代码:603087.SH)今日宣布与晶泰科技(股票代码:2228.HK)达成代谢疾病领域AI多肽创新药的研发合作及AI技术平台使用授权协议。此次合作将充分发挥甘李药业在代谢疾病领域近30年的深厚积淀与晶泰科技在AI多肽药物研发平台的领先技术优势,在AI赋能多肽药物创新与海外市场拓展中深度协同,围绕新靶点、新机制、...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.